Merck & Co.
AWARDS
NEWS
This morning, Genentech released results of its Phase III IMpower 133 trial that showed treatment with Tecentriq plus chemotherapy helped people with extensive-stage small cell lung cancer live significantly longer than with chemotherapy alone.
AstraZeneca and its MedImmune division released data on overall survival (OS) in its Phase III PACIFIC clinical trial of Imfinzi (durvalumab).
Ovarian cancer is the fifth leading cause of cancer-related deaths in the United States. It is estimated that this year there will be more than 22,000 women in the U.S. diagnosed with the disease and about 14,000 disease-related deaths.
The U.S. Food and Drug Administration (FDA) has a few target action dates scheduled for this week, including one for Sunday, September 23, which was approved in late August.
Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found. The U.S. Centers for Disease Control and Prevention published a new report in the journal Alzheimer’s & Dementia projecting the disease’s likely expansion, and for the first time, forecasted the disease by race and ethnicity.
The Morgan Stanley Global Healthcare Conference ran from September 12 through 14, with numerous biopharma companies making presentations, updating their operations and pipeline activities. Here’s a look a few of the highlights.
JOBS
IN THE PRESS